Brown University
BrUOG-430 is a prospective, single-arm, phase 2 trial evaluating yttrium-90 radioembolization in combination with capecitabine and atezolizumab for the treatment of unresectable colorectal cancer liver metastases in individuals who have been treated with two or more lines of systemic therapy.
Inclusion Criteria: 1. Histologically confirmed diagnosis of colorectal adenocarcinoma 2. Surgically unresectable, liver-isolated or liver-dominant, RECIST measurable, metastatic disease 3. Age ≥18 years at the time of signing informed consent 4. ECOG performance status 0 or 1 5. Progression on 2 or more lines of systemic therapy 6. Agreeable to providing tumor tissue and blood for exploratory correlative analyses 7. Less than 50% of liver volume replaced by metastatic disease (as determined by investigator) 8. Demonstrate adequate organ function as defined in table below (all screening labs…
yttrium-90 radioembolization in combination with capecitabine and atezolizumab for the treatment of unresectable colorectal cancer liver metastases in individuals who have been treated with two or more lines of systemic therapy.
Arctuva estimate
Verify or correct the compensation shown for this listing.